2019 RESEARCH
- Archives -UMass Medical School licenses gene therapy approach for Leber congenital amaurosis
UMass Medical School has licensed the exclusive global rights to develop and commercialize novel adeno-associated virus gene therapy product candidates for the treatment of Leber congenital amaurosis type 10 to IVERIC bio, Inc. The product was developed from research by Hemant Khanna, PhD, in collaboration with Guangping Gao, PhD.
New research from Mark Alkema lab shows how stress can weaken defenses
Research from the lab of Mark Alkema, PhD, shows how a dynamic regulation of a stress neurohormone regulates the trade-off between acute and long-term stress responses. Results of the study were published in Nature
LISTEN: Jonathan Gerber on next-generation therapies to fight cancer
Learn about the UMass Cancer Walk and Run and the latest advancements in cancer research in this Voices of UMassMed podcast with Jonathan Gerber, MD.
Hookworm infection may cause cognitive impairment earlier than thought
Human hookworm infection, even at low levels for short periods of time, can cause rapid, acute and measurable cognitive impairments in spatial memory among a mammalian animal model, according to new research from the lab of Raffi Aroian, PhD.
Dorothy Schafer honored by Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation has recognized Dorothy P. Schafer, PhD, for exceptional research of the role of microglia in regulating neural circuit structure and function as it relates to mental illness.
LISTEN: Duchenne Program at UMass Medical School provides care, advances research
Learn about the Duchenne Program at UMass Medical School in this Voices of UMassMed podcast with Brenda Wong, MD, founding director of the program, and Tracy Seckler, co-founder and CEO of Charley’s Fund.
STAT: Lyme disease preventative developed at UMMS moves closer to clinical trial
The Lyme pre-exposure prophylaxis being developed by MassBiologics at UMass Medical School may be headed to a Phase I clinical trial as soon as next year and brought to market in 2022, according to an article in STAT.
Xiaoduo Fan appointed to PCORI advisory panel on health care delivery and disparities research
Xiaoduo Fan, MD, MPH, will compare two psychosocial interventions that can result in meaningful improvement for persons with schizophrenia and related illnesses as a member of a PCORI Advisory Panel for Healthcare Delivery and Disparities Research.
Continuation of combination drug therapy for psychotic depression reduces relapse risk, JAMA study shows
Anthony Rothschild, MD, is the lead researcher at UMass Medical School on a new JAMA study that analyzes how continuation of a combination drug therapy could help patients who have major depressive disorder with psychotic features, a disabling condition with a high-risk of suicide.
Boston Globe columnist describes PhD candidate Zachary Kennedy’s personal connection to ALS research
Zachary Kennedy, PhD candidate in the Graduate School of Biomedical Sciences, is committed to advancing research toward a cure for ALS, after losing his grandfather and an uncle to the disease. Kennedy’s work is highlighted in the Boston Globe.
